14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
ZLAB vs XENE: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Xenon Pharmaceuticals Inc (XENE) captures the overall head-to-head institutional edge over Zai Lab Limited (ZLAB) on higher Unified Composite conviction (33.3/100 SELL vs. 47.4/100 HOLD) after splitting the core matrix 4–4 (led by Profitability & Quality, Options & Positioning), while ZLAB wins 4–2 across the 6-pillar growth and valuation breakdown. ZLAB trades at $23.83 (N/M Forward P/E, -63.0% operating margin) versus XENE at $39.30 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While ZLAB currently prints a higher short-term Unified Composite Score (47.4/100 HOLD vs. XENE 33.3/100 SELL), XENE captures the overall institutional head-to-head verdict (4–4 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -63.0% operating margin) and revenue trajectory (-100.0% vs. -6.8% YoY).
Technical & Structure Timing Caution: ZLAB trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 47.1); meanwhile XENE is in a Breakdown options structure phase (RSI 51.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ZLAB vs XENE. Trailing 12-month operating profitability (ZLAB -63.0% vs XENE 0.0%) and valuation multiples (ZLAB N/M vs XENE N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $4.0B market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ ZLAB vs XENE Key Questions & Quantitative Answers
As of Nov 16, 2026, Xenon Pharmaceuticals Inc (XENE) captures the overall head-to-head institutional edge over Zai Lab Limited (ZLAB) on higher Unified Composite conviction (33.3/100 SELL vs. 47.4/100 HOLD) after splitting the core matrix 4–4 (led by Profitability & Quality, Options & Positioning), while ZLAB wins 4–2 across the 6-pillar growth and valuation breakdown. ZLAB trades at $23.83 (N/M Forward P/E, -63.0% operating margin) versus XENE at $39.30 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While ZLAB currently prints a higher short-term Unified Composite Score (47.4/100 HOLD vs. XENE 33.3/100 SELL), XENE captures the overall institutional head-to-head verdict (4–4 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -63.0% operating margin) and revenue trajectory (-100.0% vs. -6.8% YoY). Technical & Structure Timing Caution: ZLAB trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 47.1); meanwhile XENE is in a Breakdown options structure phase (RSI 51.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ZLAB leads the Growth & Scale pillar: ZLAB posts -6.8% YoY revenue growth and +0.0% YoY earnings growth on $442M TTM revenue (0.6% gross margin, -63.0% operating margin), compared with XENE at -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, ZLAB generates $442M in USD-normalized revenue versus N/A for XENE. In operating R&D and SG&A reinvestment, ZLAB deploys 63.6% of Rev ($281M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for XENE.
ZLAB screens cheaper on headline valuation multiples. ZLAB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 6.8x EV/Revenue (-59.3% EBITDA margin), whereas XENE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ZLAB (-30.0% ROE) versus XENE (-50.3% ROE) capital efficiency.
In options market volatility and institutional positioning, ZLAB carries 58.4% implied volatility (58th %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.19β · 78% Vol realized risk). By comparison, XENE carries 57.6% implied volatility (14th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (0.70β · 36% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.